You have accessJournal of UrologyProstate Cancer: Localized IV1 Apr 2012991 THE RATE OF ADVERSE DISEASE AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY IN PATIENTS ELIGIBLE FOR ACTIVE SURVEILLANCE Jan Schmitges, Hans Heinzer, Lars Budäus, Pierre Tennstedt, Jens Hansen, Quoc-Dien Trinh, Thorsten Schlomm, Thomas Steuber, Georg Salomon, Lothar Weissbach, Hartwig Huland, Markus Graefen, and Felix K. Chun Jan SchmitgesJan Schmitges Hamburg, Germany More articles by this author , Hans HeinzerHans Heinzer Hamburg, Germany More articles by this author , Lars BudäusLars Budäus Hamburg, Germany More articles by this author , Pierre TennstedtPierre Tennstedt Hamburg, Germany More articles by this author , Jens HansenJens Hansen Hamburg, Germany More articles by this author , Quoc-Dien TrinhQuoc-Dien Trinh Detroit, MI More articles by this author , Thorsten SchlommThorsten Schlomm Hamburg, Germany More articles by this author , Thomas SteuberThomas Steuber Hamburg, Germany More articles by this author , Georg SalomonGeorg Salomon Hamburg, Germany More articles by this author , Lothar WeissbachLothar Weissbach Berlin, Germany More articles by this author , Hartwig HulandHartwig Huland Hamburg, Germany More articles by this author , Markus GraefenMarkus Graefen Hamburg, Germany More articles by this author , and Felix K. ChunFelix K. Chun Hamburg, Germany More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1092AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Criteria defining patient's eligibility for active surveillance (AS) may include low and intermediate risk prostate cancer. It is unknown whether more liberal AS criteria translate into adverse outcomes after AS and definitive treatment. METHODS We assessed outcomes after radical prostatectomy (RP) in men who preoperatively met at least one of eight currently used AS criteria. We report rates of extracapsular extension (ECE), seminal vesicle (SVI) and lymph node invasion (LNI), Gleason score >6, and biochemical recurrence (BCR) according to eight different study cohorts. RESULTS Between January 2002 and January 2010 1,554 patients who met at least one of eight AS criteria were treated with RP at a single European institution. The median follow-up was 48 months. The ECE and SVI rates ranged from 7.0 to 17.2% and from 1.6 to 3.5%, respectively. The LNI and Gleason score >6 rates ranged from 0.2 to 0.7% and from 34.1% to 55.0%, respectively. Biochemical recurrence rates ranged from 4.3% to 7.7%. CONCLUSIONS Although rates of adverse disease within all cohorts are high, BCR rates are lower 10%. New predictive models are needed to select patients for AS. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e403 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jan Schmitges Hamburg, Germany More articles by this author Hans Heinzer Hamburg, Germany More articles by this author Lars Budäus Hamburg, Germany More articles by this author Pierre Tennstedt Hamburg, Germany More articles by this author Jens Hansen Hamburg, Germany More articles by this author Quoc-Dien Trinh Detroit, MI More articles by this author Thorsten Schlomm Hamburg, Germany More articles by this author Thomas Steuber Hamburg, Germany More articles by this author Georg Salomon Hamburg, Germany More articles by this author Lothar Weissbach Berlin, Germany More articles by this author Hartwig Huland Hamburg, Germany More articles by this author Markus Graefen Hamburg, Germany More articles by this author Felix K. Chun Hamburg, Germany More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...